Clinical studies of patients with mild cognitive impairment (MCI) and AD have found higher levels of plasma clusterin in cases compared to controls, and associations between higher clusterin and smaller tissue volumes in multiple brain areas, particularly the entorhinal cortex and hippocampus, which are known to change with AD. This evidence concerns the gene CLU and Alzheimer disease.